Locally advanced pancreatic cancer: The role of definitive chemoradiotherapy

Clinical Oncology

Volumn 26, Issue 9, 2014, Pages 560-568

  Huguet, F ^a   Mukherjee, S ^b   Javle, M ^c  

^a ARMAND TROUSSEAU HOSPITAL   (France)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Chemoradiotherapy; Gemcitabine; Locally advanced; Pancreatic adenocarcinoma; Radiotherapy; Review

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IRINOTECAN; MITOMYCIN; MOLECULAR MARKER; OXALIPLATIN; PACLITAXEL;

ADVANCED CANCER; ARTICLE; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CHEMORADIOTHERAPY; DRUG MEGADOSE; HUMAN; META ANALYSIS (TOPIC); MOLECULARLY TARGETED THERAPY; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMIC THERAPY; PANCREATIC NEOPLASMS;

CHEMORADIOTHERAPY; HUMANS; PANCREATIC NEOPLASMS;

EID: 84905573934     PISSN: 09366555     EISSN: 14332981     Source Type: Journal    
DOI: 10.1016/j.clon.2014.06.002     Document Type: Article

References (62)

1. Gudjonsson B. Cancer of the pancreas. 50 years of surgery. Cancer 1987, 60:2284-2303.
2. Yeo T.P., Hruban R.H., Leach S.D., et al. Pancreatic cancer. Curr Probl Cancer 2002, 26:176-275.
3. Varadhachary G.R., Tamm E.P., Abbruzzese J.L., et al. Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy. Ann Surg Oncol 2006, 13:1035-1046.
4. Moertel C.G., Frytak S., Hahn R.G., et al. Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil: The Gastrointestinal Tumor Study Group. Cancer 1981, 48:1705-1710.
5. Burris H.A., Moore M.J., Andersen J., et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997, 15:2403-2413.
6. Hazel J.J., Thirlwell M.P., Huggins M., et al. Multi-drug chemotherapy with and without radiation for carcinoma of the stomach and pancreas: a prospective randomized trial. J Can Assoc Radiol 1981, 32:164-165.
7. Klaassen D.J., MacIntyre J.M., Catton G.E., et al. Treatment of locally unresectable cancer of the stomach and pancreas: a randomized comparison of 5-fluorouracil alone with radiation plus concurrent and maintenance 5-fluorouracil-an Eastern Cooperative Oncology Group study. J Clin Oncol 1985, 3:373-378.
8. Gastrointestinal Tumor Study Group Treatment of locally unresectable carcinoma of the pancreas: comparison of combined-modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone. J Natl Cancer Inst 1988, 80:751-755.
9. Chauffert B., Mornex F., Bonnetain F., et al. Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000-01 FFCD/SFRO study. Ann Oncol 2008, 19:1592-1599.
10. Loehrer P.J., Feng Y., Cardenes H., et al. Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial. J Clin Oncol 2011, 29:4105-4112.
11. Huguet F., Girard N., Guerche C.S., et al. Chemoradiotherapy in the management of locally advanced pancreatic carcinoma: a qualitative systematic review. J Clin Oncol 2009, 27:2269-2277.
12. Sultana A., Smith C.T., Cunningham D., et al. Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer. J Clin Oncol 2007, 25:2607-2615.
13. Yip D., Karapetis C., Strickland A., et al. Chemotherapy and radiotherapy for inoperable advanced pancreatic cancer. The Cochrane Library 2007, 1-72.
14. Ko A.H., Quivey J.M., Venook A.P., et al. A phase II study of fixed-dose rate gemcitabine plus low-dose cisplatin followed by consolidative chemoradiation for locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 2007, 68:809-816.
15. Huguet F., Andre T., Hammel P., et al. Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase II and III studies. J Clin Oncol 2007, 25:326-331.
16. Krishnan S., Rana V., Janjan N.A., et al. Induction chemotherapy selects patients with locally advanced, unresectable pancreatic cancer for optimal benefit from consolidative chemoradiation therapy. Cancer 2007, 110:47-55.
17. Hammel P., Huguet F., Van Laethem J., et al. Randomized multicenter phase III study in patients with locally advanced adenocarcinoma of the pancreas: gemcitabine with or without chemoradiotherapy and with or without erlotinib-LAP 07 study. ASCO Meeting Abstracts 2013, 29:e14619.
18. Kindler H.L., Niedzwiecki D., Hollis D., et al. Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J Clin Oncol 2010, 28:3617-3622.
19. Philip P.A., Benedetti J., Corless C.L., et al. Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205. J Clin Oncol 2010, 28:3605-3610.
20. Louvet C., Labianca R., Hammel P., et al. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Clin Oncol 2005, 23:3509-3516.
21. Rocha Lima C.M., Green M.R., Rotche R., et al. Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. J Clin Oncol 2004, 22:3776-3783.
22. Conroy T., Desseigne F., Ychou M., et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011, 364:1817-1825.
23. Von Hoff D.D., Ervin T., Arena F.P., et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 2013, 369:1691-1703.
24. Marthey L., Sa Cunha A., Blanc J.F., et al. FOLFIRINOX for locally advanced pancreatic carcinoma. Results of an AGEO multicenter prospective study. Ann Oncol 2013, 24:iv12.
25. Cooray P., Dean A.P. Neoadjuvant therapy with nanoparticle albumin-bound (nab)-paclitaxel to enhance the resectability of locally advanced pancreatic cancer (LAPC). ASCO Meeting Abstracts 2012, 30:e14644.
26. Kunzmann V., Hartlapp I., Scheurlen M., et al. Sequential neoadjuvant chemotherapy with nab-paclitaxel plus gemcitabine and FOLFIRINOX in locally advanced pancreatic cancer (LAPC): A PILOT study. ASCO Meeting Abstracts 2013, 31:e15193.
27. Poen J.C., Collins H.L., Niederhuber J.E., et al. Chemo-radiotherapy for localized pancreatic cancer: increased dose intensity and reduced acute toxicity with concomitant radiotherapy and protracted venous infusion 5-fluorouracil. Int J Radiat Oncol Biol Phys 1998, 40:93-99.
28. Zhu C.P., Shi J., Chen Y.X., et al. Gemcitabine in the chemoradiotherapy for locally advanced pancreatic cancer: a meta-analysis. Radiother Oncol 2011, 99:108-113.
29. Mukherjee S., Hurt C.N., Bridgewater J., et al. Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): a multicentre, randomised, phase 2 trial. Lancet Oncol 2013, 14:317-326.
30. McGinn C.J., Zalupski M.M., Shureiqi I., et al. Phase I trial of radiation dose escalation with concurrent weekly full-dose gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol 2001, 19:4202-4208.
31. Murphy J.D., Adusumilli S., Griffith K.A., et al. Full-dose gemcitabine and concurrent radiotherapy for unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys 2007, 68:801-808.
32. Huang J., Robertson J.M., Margolis J., et al. Long-term results of full-dose gemcitabine with radiation therapy compared to 5-fluorouracil with radiation therapy for locally advanced pancreas cancer. Radiother Oncol 2011, 99:114-119.
33. Ben-Josef E., Schipper M., Francis I.R., et al. A phase I/II trial of intensity modulated radiation (IMRT) dose escalation with concurrent fixed-dose rate gemcitabine (FDR-G) in patients with unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys 2012, 84:1166-1171.
34. Moutardier V., Magnin V., Turrini O., et al. Assessment of pathologic response after preoperative chemoradiotherapy and surgery in pancreatic adenocarcinoma. Int J Radiat Oncol Biol Phys 2004, 60:437-443.
35. Gillen S., Schuster T., Meyer Zum Buschenfelde C., et al. Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. PLoS Med 2010, 7:e1000267.
36. Iannitti D., Dipetrillo T., Akerman P., et al. Erlotinib and chemoradiation followed by maintenance erlotinib for locally advanced pancreatic cancer: a phase I study. Am J Clin Oncol 2005, 28:570-575.
37. Duffy A., Kortmansky J., Schwartz G.K., et al. A phase I study of erlotinib in combination with gemcitabine and radiation in locally advanced, non-operable pancreatic adenocarcinoma. Ann Oncol 2008, 19:86-91.
38. Arnoletti J.P., Frolov A., Eloubeidi M., et al. A phase I study evaluating the role of the anti-epidermal growth factor receptor (EGFR) antibody cetuximab as a radiosensitizer with chemoradiation for locally advanced pancreatic cancer. Cancer Chemother Pharmacol 2011, 67:891-897.
39. Crane C.H., Varadhachary G.R., Yordy J.S., et al. Phase II trial of cetuximab, gemcitabine, and oxaliplatin followed by chemoradiation with cetuximab for locally advanced (T4) pancreatic adenocarcinoma: correlation of Smad4(Dpc4) immunostaining with pattern of disease progression. J Clin Oncol 2011, 29:3037-3043.
40. Crane C.H., Ellis L.M., Abbruzzese J.L., et al. Phase I trial evaluating the safety of bevacizumab with concurrent radiotherapy and capecitabine in locally advanced pancreatic cancer. J Clin Oncol 2006, 24:1145-1151.
41. Crane C.H., Winter K., Regine W.F., et al. Phase II study of bevacizumab with concurrent capecitabine and radiation followed by maintenance gemcitabine and bevacizumab for locally advanced pancreatic cancer: Radiation Therapy Oncology Group RTOG 0411. J Clin Oncol 2009, 27:4096-4102.
42. Pajonk F., Himmelsbach J., Riess K., et al. The human immunodeficiency virus (HIV)-1 protease inhibitor saquinavir inhibits proteasome function and causes apoptosis and radiosensitization in non-HIV-associated human cancer cells. Cancer Res 2002, 62:5230-5235.
43. Gupta A.K., Cerniglia G.J., Mick R., et al. HIV protease inhibitors block Akt signaling and radiosensitize tumor cells both in vitro and in vivo. Cancer Res 2005, 65:8256-8265.
44. Plastaras J.P., Vapiwala N., Ahmed M.S., et al. Validation and toxicity of PI3K/Akt pathway inhibition by HIV protease inhibitors in humans. Cancer Biol Ther 2008, 7:628-635.
45. Brunner T.B., Geiger M., Grabenbauer G.G., et al. Phase I trial of the human immunodeficiency virus protease inhibitor nelfinavir and chemoradiation for locally advanced pancreatic cancer. J Clin Oncol 2008, 26:2699-2706.
46. Rengan R., Mick R., Pryma D., et al. A phase I trial of the HIV protease inhibitor nelfinavir with concurrent chemoradiotherapy for unresectable stage IIIA/IIIB non-small cell lung cancer: a report of toxicities and clinical response. J Thorac Oncol 2012, 7:709-715.
47. Minn A.Y., Koong A.C., Chang D.T. Stereotactic body radiation therapy for gastrointestinal malignancies. Front Radiat Ther Oncol 2011, 43:412-427.
48. Mahadevan A., Miksad R., Goldstein M., et al. Induction gemcitabine and stereotactic body radiotherapy for locally advanced nonmetastatic pancreas cancer. Int J Radiat Oncol Biol Phys 2011, 81:e615-e622.
49. Chang D.T., Schellenberg D., Shen J., et al. Stereotactic radiotherapy for unresectable adenocarcinoma of the pancreas. Cancer 2009, 115:665-672.
50. Gurka M.K., Collins S.P., Slack R., et al. Stereotactic body radiation therapy with concurrent full-dose gemcitabine for locally advanced pancreatic cancer: a pilot trial demonstrating safety. Radiat Oncol 2013, 8:44.
51. Chuong M.D., Springett G.M., Freilich J.M., et al. Stereotactic body radiation therapy for locally advanced and borderline resectable pancreatic cancer is effective and well tolerated. Int J Radiat Oncol Biol Phys 2013, 86:516-522.
52. Iacobuzio-Donahue C.A., Fu B., Yachida S., et al. DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer. J Clin Oncol 2009, 27:1806-1813.
53. Moertel C.G., Childs D.S., Reitemeier R.J., et al. Combined 5-fluorouracil and supervoltage radiation therapy of locally unresectable gastrointestinal cancer. Lancet 1969, 2:865-867.
54. Radiation therapy combined with Adriamycin or 5-fluorouracil for the treatment of locally unresectable pancreatic carcinoma. Gastrointestinal Tumor Study Group. Cancer 1985, 56:2563-2568.
55. Earle J.D., Foley J.F., Wieand H.S., et al. Evaluation of external-beam radiation therapy plus 5-fluorouracil (5-FU) versus external-beam radiation therapy plus hycanthone (HYC) in confined, unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys 1994, 28:207-211.
56. Shinchi H., Takao S., Noma H., et al. Length and quality of survival after external-beam radiotherapy with concurrent continuous 5-fluorouracil infusion for locally unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys 2002, 53:146-150.
57. Chung H.W., Bang S.M., Park S.W., et al. A prospective randomized study of gemcitabine with doxifluridine versus paclitaxel with doxifluridine in concurrent chemoradiotherapy for locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 2004, 60:1494-1501.
58. Cohen S.J., Dobelbower R., Lipsitz S., et al. A randomized phase III study of radiotherapy alone or with 5-fluorouracil and mitomycin-C in patients with locally advanced adenocarcinoma of the pancreas: Eastern Cooperative Oncology Group study E8282. Int J Radiat Oncol Biol Phys 2005, 62:1345-1350.
59. Boone B.A., Steve J., Krasinskas A.M., et al. Outcomes with FOLFIRINOX for borderline resectable and locally unresectable pancreatic cancer. J Surg Oncol 2013, 108:236-241.
60. Conroy T., Gavoille C., Samalin E., et al. The role of the FOLFIRINOX regimen for advanced pancreatic cancer. Curr Oncol Rep 2013, 15:182-189.
61. Faris J.E., Wo J.Y. The controversial role of chemoradiation for patients with locally advanced pancreatic cancer. Oncologist 2013, 18:981-985.
62. Hosein P.J., Macintyre J., Kawamura C., et al. A retrospective study of neoadjuvant FOLFIRINOX in unresectable or borderline-resectable locally advanced pancreatic adenocarcinoma. BMC Cancer 2012, 12:199.